Why IMU is a multi multi bagger, page-9096

Results in significant tumor killing

In this my 100th post I want to focus front and centre on what for me is the most important news story to capture my attention during my time analysing Imugene. For those familar with Imugene (ASX - IMU) read closely and for those unfamiliar with the company, read even closer, for put simply this is mind blowing stuff.

This time one year ago Imugene (IMU-ASX) made one of the most ground breaking announcements in the history of cancer research when stating through their partners at the City of Hope Compehensive Cancer Centre
“By combining oncolytic virus and CAR T-cell therapies, we have developed a ‘mark and kill’ approach to treating solid tumours with T-cell therapies”. At the time Dr. Saul Priceman, Ph.D., Assistant Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope and co-inventor of the platform noted “In our animal studies, we were able to express CD19 in triple-negative breast, pancreatic, prostate, ovarian, and head and neck cancer, as well as brain tumours.”

Ground breaking technology

The full details of this news can be viewed in thesource version on businesswire.com: https://www.businesswire.com/news/home/20211101005254/en/ . If you are interested in cancer research, medical advancements, Imugene the stock or game changing technology I suggest you read the article in full.

November 01, 2021 08:00 AM Eastern Daylight Time

SYDNEY & EMERYVILLE, Calif.--(BUSINESS WIRE)--Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company, and Eureka Therapeutics, Inc. (“Eureka”), a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumours, today announced a strategic collaboration to evaluate Imugene’s CD19 oncolytic virus onCARlytics technology in combination with Eureka’s anti-CD19 ARTEMIS® T-cell therapy for the treatment of solid tumours.

Oncolytic viruses in combination with T-cell therapies represent a novel and promising approach to treat solid tumours. In preclinical studies conducted by the City of Hope Comprehensive Cancer Center, scientists combined CAR-T therapy with an oncolytic virus to eliminate solid tumours in mice. The virus enters the tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for anti-CD19 T-cells to pursue and kill. Imugene licensed the patents covering City of Hope’s oncolytic virus technology in May 2021.

“By combining oncolytic virus and CAR T-cell therapies, we have developed a ‘mark and kill’ approach to treating solid tumours with T-cell therapies,” said Saul Priceman, Ph.D., Assistant Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope and co-inventor of the platform. “In our animal studies, we were able to express CD19 in triple-negative breast, pancreatic, prostate, ovarian, and head and neck cancer, as well as brain tumours.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005254/en/

“T-cell and CAR-T therapies have not achieved much success in solid tumours in part because of a lack of tumour-specific targets. By using our proprietary oncolytic technology to force the tumour to express the CD19 target, we now have the ability to address this shortcoming. We believe the synergy between our onCARlytics platform and Eureka’s anti-CD19 ARTEMIS® T-cells has the potential to shift the cellular medicine paradigm in treating solid tumours,” said Leslie Chong, Managing Director & Chief Executive Officer of Imugene.

“We are delighted to be working with Imugene on tackling solid tumours using this innovative approach,” said Dr. Cheng Liu, President and CEO of Eureka Therapeutics. “We believe our ARTEMIS® T-cell platform to be the ideal one to evaluate this combination. In head-to-head pre-clinical studies against CAR-T cells, our ARTEMIS® T-cells demonstrated superior efficacy, enhanced tumour infiltration, and less T-cell exhaustion. In the clinical context, our ARTEMIS® T-cells have demonstrated reduced cytokine release syndrome (CRS) and other cytokine-related toxicities compared to CAR-T cells, potentially improving the efficacy and safety of a combination approach.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005254/en/

How big is the solid tumour market?

By way of background according to Data Bridge Market Research see https://www.databridgemarketresearch.com/reports/global-solid-tumors-market solid tumors are created by the accumulation of aberrant tissues that do not contain any liquid or cyst in the case of cancer. There are two types of solid tumors: benign and malignant. The treatment of solid tumors is difficult, and it necessitates coordinated actions by a variety of healthcare professionals, including surgeons, radiologists, radiation specialists, oncologists, and others.As a result, chemotherapy, radiation,and/or surgery are used to treat the majority of solid tumors.

Data Bridge Market Research analyses that the solid tumors market was valued at USD 209.61 billion in 2021 and is expected to reach USD 901.27 billion by 2029, registering a CAGR of 20.0% during the forecast period of 2022 to 2029.

see https://www.databridgemarketresearch.com/reports/global-solid-tumors-market

To put these numbers in perspective the global electric car market was valued at USD 105 billion in 2021 and is likely to surpass USD 354.80 billion by 2028, exhibiting a CAGR of 19% during the forecast period 2022-2028. Sales of electric cars are generally higher in the second half of the year. Today he world’s leading car manufacturer Tesla is valued at 705.44 USD.

When do the results of this game changing medicine come to light?

At the forthcoming SITC 2022 meeting in Boston from November 8 to 12 Imugene is presenting details of their collaboration with Eureka Therapeutics in a poster presentaion entitled :

Title: CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with Artemis® CD19 T cells results in significant tumor killing.

What is Imugene saying about this revolutionary breakthrough?

I draw your attention to Imugene CEO Lesley Chong’s excitement surrounding the pending release of information on the oncarlytics collaborations with not only Eureka Therapeutics, but with Celularity (CELU -NASDAQ), approximately 9 minutes into this YouTube video courtesy of

Kalkine Media (kalkinemedia.com)

Without wishing to sound to over dramatic forgive me for saying this is clearly an historical moment in the evolution of mankind. Cancer has been decimating our population for years, through all manner of solid tumours. Every year each of us lose someone we know or someone we are close to as a result of this dreaded disease. To think that Imugene, Saul “Cancer Asskicker” Priceman (@SaulPriceman) / Twitter and Yuman Fong M.D. may have found a solution to eliminating and indeed obliterating solid tumours in humans is something to behold.

Where to now for Imugene (IMU)

For some time now the Imugene share price and those analysing the stock have failed to attribute any monetary value to Yuman Fong’s CF33, Vaxinia and oncolytic viruses in their reports. Surely now as November’s pending SIT Conference poster presentations approach and as CF33 trial results into triple negative breast cancer patients (TNBC) are announced, the market can no longer ignore this novel technology. Surely Big Pharma, Car T providers and sophisticated investors worldwide are soon to come knocking (if not break down the door) when this “front page news” arrives on their doorstep.

Brick by brick the team at Imugene has been building and developing their immunotherapy based platforms to fight cancer in humans. This is clearly a watershed moment for the company as their flagship product CF33 is now realising its true potential in combination with the Oncarlytics - CD19 - Car T treatment arm.

Is this November and the results of their trials and tribulations with CF33 and Oncarlytics the tipping point for IMU?

Well to answer that question my mind wanders back to days spent with my father trawling around the bush chasing cows, calves and later steers, from which a saying comes to mind “You can lead a horse to water, but you can’t make it drink”.

DYOR - Seek investment advice where necessary - Opinions only